Phase 1
Completed N=57
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
Pediculosis
Source: ClinicalTrials.gov NCT01518699 ↗
Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcomePrimary: Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF — -9.7; -9.2; 6.1 milliseconds
Summary
The purpose of this study is to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference Between Active and Placebo for Time Matched Baseline Adjusted Mean QTcF |
-9.7; -9.2; 6.1 | — |
Eligibility Criteria
Inclusion Criteria
- healthy male or female subject, 18 to 50 years of age, inclusive, at least 45 kg and has a body mass index (BMI) of 18 to 33 kg/m2,
- Female subjects of childbearing potential must not be pregnant and not lactating or prepared to practice highly effective birth control methods
- The subject has normal 12-lead ECG results or, if abnormal, the abnormality is not clinically significant (as determined by the investigator).
Exclusion Criteria
- has evidence of cardiac conduction abnormalities
- history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative due to cardiac causes at a young age
- potassium, calcium, or magnesium levels that are below the clinical laboratory's lower limit of normal
- laboratory test results at Screening are >2 x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), >1.5 x ULN for bilirubin, or >1.5 x ULN for creatinine
- history or evidence of any clinically significant (as determined by the investigator) cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy (excluding non-melanoma skin cancer)
- febrile illness or symptomatic viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week before clinic admission
- supine mean systolic blood pressure 140 mmHg and a mean diastolic blood pressure 90 mmHg
- positive for HIV or hepatitis C antibody or hepatitis B antigen (HBsAg)
Data sourced from ClinicalTrials.gov (NCT01518699). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.